KYMR (NASDAQ) insider files to sell 80,000 shares after option exercise
Rhea-AI Filing Summary
KYR Medicines, Inc. (KYMR) reported a Section 144 notice indicating an intended sale of 80,000 shares of Common Stock on 07/01/2026 arising from an exercise of stock options with cash as the payment method. The filing also records a prior sale of 30,000 shares on 04/29/2026.
The filing lists an aggregate dollar figure of $9,143,200.00 and a share count of 82,257,588 tied to 07/01/2026. The notice names Nello Mainolfi in the recent sale record.
Positive
- None.
Negative
- None.
Insights
Form 144 discloses an option-related sale plan and a recent insider sale.
The filing shows an intended disposition of 80,000 shares on 07/01/2026 described as resulting from an exercise of stock options with cash noted as the payment type. It also records a prior sale of 30,000 shares on 04/29/2026.
Cash‑flow treatment and whether the 80,000 shares will be sold in the open market or via other methods is not detailed in the excerpt; subsequent regulatory filings or broker confirmations may disclose execution method and timing.